|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer
This item is licensed under:Creative Commons Attribution 4.0 International
| Title: | Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer |
| Authors: | Dong, Peixin Browse this author →KAKEN DB | | Xiong, Ying Browse this author | | Yu, Jiehai Browse this author | | Chen, Lin Browse this author | | Tao, Tang Browse this author | | Yi, Song Browse this author | | Hanley, Sharon J.B. Browse this author →KAKEN DB | | Yue, Junming Browse this author | | Watari, Hidemichi Browse this author →KAKEN DB | | Sakuragi, Noriaki Browse this author →KAKEN DB |
| Issue Date: | 27-Sep-2018 |
| Publisher: | Nature Publishing Group |
| Journal Title: | Oncogene |
| Volume: | 37 |
| Issue: | 39 |
| Start Page: | 5257 |
| End Page: | 5268 |
| Publisher DOI: | 10.1038/s41388-018-0347-4 |
| Abstract: | PD-L1, a key inhibitory immune receptor, has crucial functions in cancer immune evasion, but whether PD-L1 promotes the malignant properties of cervical cancer (CC) cells and the mechanism by which PD-L1 is regulated in CC remains unclear. We report that PD-L1 is overexpressed in CC, and shRNA-mediated PD-L1 depletion suppresses the proliferation, invasion, and tumorigenesis of CC cells. Loss of miR-140/142/340/383 contributes to PD-L1 upregulation. miR-18a enhances PD-L1 levels by targeting PTEN, WNK2 (ERK1/2 pathway inhibitor), and SOX6 (Wnt/β-catenin pathway inhibitor and p53 pathway activator) to activate the PI3K/AKT, MEK/ERK, and Wnt/β-catenin pathways and inhibit the p53 pathway, and miR-18a also directly suppresses the expression of the tumor suppressors BTG3 and RBSP3 (CTDSPL). miR-18a overexpression in CC cells is triggered by OCT4 overexpression. Our data implicate PD-L1 as a novel oncoprotein and indicate that miR-140/142/340/383 and miR-18a are key upstream regulators of PD-L1 and potential targets for CC treatment. |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/71539 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 董 培新
|
